Improving treatment options for Trichomonas vaginalis infections in men and women.
Refining Trichomonas vaginalis treatment in women and men.
This study is looking at a new single-dose medicine called secnidazole to see if it works better than the usual multi-dose treatment for Trichomonas vaginalis, a common infection that can cause health problems, and it's for both men and women who are dealing with this issue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11061219 on NIH RePORTER |
What this research studies
This research focuses on enhancing the treatment of Trichomonas vaginalis, a common sexually transmitted infection that can lead to serious health issues. The study aims to compare the effectiveness of a new single-dose medication, secnidazole, against the current multi-dose treatment, metronidazole, which has shown high rates of treatment failure. By including both men and women in the trials, the research seeks to provide a more comprehensive understanding of effective treatments for this infection. Patients will be monitored for treatment outcomes and any potential side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Trichomonas vaginalis, particularly those who have not responded well to existing treatments.
Not a fit: Patients who do not have Trichomonas vaginalis or those who have already been successfully treated with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and convenient treatment options for Trichomonas vaginalis, reducing the incidence of treatment failures.
How similar studies have performed: Previous studies have shown promising results with similar treatment approaches, indicating potential for success in refining Trichomonas vaginalis treatment.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Kissinger, Patricia J — Tulane University of Louisiana
- Study coordinator: Kissinger, Patricia J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.